? MICROSCOPY SHARED RESOURCE (MSR) The MSR provides timely and high-quality services to support OSUCCC investigators with access to instrument, technical advice and training support on a variety of sophisticated microscopy approaches. The MSR instrumentation is provided in a centrally-organized resource and all the equipment is available to OSUCCC membership with training. At the last review, the MSR was part of the Diagnostics Shared Resource Group, which was rated as Outstanding with minor comments about leadership and usage that have been addressed. During the current grant cycle, there was a significant investment in acquiring electron microscopy (cryogenic, transmission and scanning electron microscopes) and confocal live cell imaging, including enhanced super- resolution (SIM, STORM, TIRF) light microscopy capabilities funded through an NIH S10 equipment grant.
The Specific Aims of the MSR are to: 1) provide a means for OSUCCC research community to obtain publication quality, higher resolution images of their cancer research for use in manuscripts and grant applications; 2) provide training to investigators for independent use of the instruments following training; 3) provide education and consultation opportunities to OSUCCC researchers for improved sample preparation, imaging techniques and image analysis; and, as a Developing Aim to provide OSUCCC members access to cryo-electron microscopy (cryo-EM). For this Developing Aim, the OSCUCC contributed to the purchase of two instruments with sub- nanometer resolution of purified and cellular particles. During the five-year grant period, the MSR has supported 319 investigators (32% OSUCCC members), and provided 5,730 hours of service and 44,605 hours of instrument time (33.3% of which was to OSUCCC members). The MSR contributed to 192 publications (32 > 10 impact factor) and 8 NCI grants (2 K22s, 1 P01, 1 P50, 8 R01s, and 1 U01). The MSR will support the microscopy needs of all OSUCCC strategic priorities. Given the robust OSUCCC recruitment, demand for services and new technologies will increase and capacity will be expanded. To align with immuno-oncology needs, the MSR will be a regular member of the Immune Monitoring and Discovery Platform (IMDP), and two-photon microscopes will be updated. Separately, the MSR is developing cryo-FIB capability for CET studies, and it will develop correlative light and electron microscopy and real-time single molecule cellular imaging platforms in collaboration with the GEdSR. Last, the MSR and GSR has been awarded a new grant to provide imaging capabilities that supports cell enrichment and single cell sequencing. The MSR is supported by outstanding institutional resources obtained by leveraging extensive partnerships with the OSUCCC, OSU Colleges, the OSU Office of Research and grants from the State of Ohio, all totaling over $2M over the prior grant period. The annual budget of the MSR is $697,706, yet the CCSG request is $82,192. As such, the MSR seeks only 11.8% budgetary support from CCSG funds.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
United States
Zip Code
Shu, Yi; Yin, Hongran; Rajabi, Mehdi et al. (2018) RNA-based micelles: A novel platform for paclitaxel loading and delivery. J Control Release 276:17-29
Scoville, Steven D; Nalin, Ansel P; Chen, Luxi et al. (2018) Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132:1792-1804
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Schimizzi, Gregory V; Jin, Linda X; Davidson 4th, Jesse T et al. (2018) Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. HPB (Oxford) 20:332-339
Fu, Xinping; Tao, Lihua; Wang, Pin-Yi et al. (2018) Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget 9:21348-21358
Brewington, Beatrice Y; Shao, Yusra F; Davidorf, Fredrick H et al. (2018) Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions. Clin Ophthalmol 12:925-934
Doogan, Nathan J; Cooper, Sarah; Quisenberry, Amanda J et al. (2018) The role of travel distance and price promotions in tobacco product purchase quantity. Health Place 51:151-157
Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718
Oblinger, Janet L; Burns, Sarah S; Huang, Jie et al. (2018) Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol 299:299-307
Pan, Pan; Oshima, Kiyoko; Huang, Yi-Wen et al. (2018) Loss of FFAR2 promotes colon cancer by epigenetic dysregulation of inflammation suppressors. Int J Cancer 143:886-896

Showing the most recent 10 out of 2602 publications